Unweighable Remedies: The Philosophical Architecture That Made Indigenous Medicine Invisible to American Science
The Standard That Was Never Standard
In the mid-twentieth century, American medicine consolidated around a particular vision of what counted as proof. The randomized controlled trial—the RCT—ascended to the apex of the evidence hierarchy, and with it came a set of embedded philosophical commitments that have rarely been subjected to the scrutiny they deserve. Chief among those commitments was the assumption that therapeutic efficacy must be isolable: that a single intervention, stripped of context, practitioner relationship, ritual, and ecological embeddedness, could be tested against a neutral control and judged accordingly. That assumption was not derived from universal principles of reason. It was a historically specific philosophical wager, and it came with costs that the dominant tradition has been slow to acknowledge.
Indigenous healing practices—whether those of the Navajo Nation, the Haudenosaunee Confederacy, or the dozens of other nations whose medical traditions predate European contact by millennia—do not, as a rule, lend themselves to this kind of decomposition. Healing in many of these traditions is understood as relational, contextual, and inseparable from the social and spiritual fabric within which it occurs. A ceremony is not a pill. A healer's presence is not an inert placebo. The very categories the RCT requires—discrete intervention, blinded subject, replicable protocol—presuppose a model of causation that many Indigenous epistemologies explicitly reject.
This is not merely a logistical incompatibility. It is a philosophical one. And understanding it requires attending to the intellectual history of how the RCT came to occupy the position it holds.
Constructing the Gold Standard
The genealogy of the RCT runs through British statistician Austin Bradford Hill's landmark 1948 streptomycin trial, through the post-war consolidation of biostatistics as a disciplinary authority within medicine, and into the American regulatory apparatus that made RCT-level evidence a prerequisite for drug approval by the Food and Drug Administration. Each of these developments reinforced a particular epistemological architecture: that knowledge about therapeutic efficacy must be produced through controlled experimentation, quantified, and reproducible across populations abstracted from local particularity.
Philosophers of science have long recognized that all methods carry ontological commitments—assumptions about what kinds of things exist and how they interact. The RCT's ontological commitments include a mechanistic model of the body, a separability assumption about interventions, and a statistical framework that treats individual variation as noise rather than signal. These commitments work tolerably well for pharmaceutical molecules. They work considerably less well for therapeutic systems organized around principles of holism, relationality, and ecological attunement.
When the American medical licensing apparatus adopted RCT-derived evidence as its standard of legitimacy in the latter decades of the twentieth century, it did not do so after a philosophical debate about the limits of that standard. It did so through institutional accretion—through the gradual alignment of insurance reimbursement structures, licensure requirements, malpractice liability frameworks, and hospital credentialing protocols around a single evidentiary model. The result was not a reasoned adjudication between competing epistemologies. It was the quiet administrative erasure of alternatives.
What the Trial Cannot See
Consider what happens when researchers attempt to evaluate the efficacy of traditional plant-based remedies used by Indigenous healers in the American Southwest. The RCT framework demands isolation: identify the active compound, synthesize or extract it, administer it under controlled conditions, measure outcomes against a placebo group. This process is not simply reductive—it is, from the standpoint of the tradition being studied, a category error. The remedy in question may be understood to function through a combination of the plant's properties, the healer's intention, the patient's spiritual preparation, and the communal context of administration. Extracting a single compound and testing it in isolation does not test the remedy. It tests something else entirely, and then reports the results as if the original tradition had been evaluated and found wanting.
This dynamic has real consequences. When such trials return null or inconclusive results, the failure is attributed to the Indigenous practice rather than to the methodological mismatch between the practice and the evaluative framework. The practice is recorded as lacking evidence of efficacy. It enters no formulary, receives no insurance coverage, earns no legitimacy within the licensing regime—not because it was shown to be ineffective, but because it was shown to be unmeasurable by instruments not designed to measure it.
The philosopher Helen Longino's work on the social dimensions of scientific knowledge is instructive here. Longino argued that what counts as evidence is always relative to a background framework of assumptions, and that those assumptions are themselves subject to social and political influence. The RCT's rise to dominance was not epistemologically inevitable. It was the product of specific institutional choices made by specific actors within a specific historical moment—a moment shaped by the professionalization of American medicine, the expansion of federal regulatory authority, and the marginalization of non-biomedical traditions through both formal policy and informal professional culture.
The Epistemology of Exclusion
What makes this history philosophically significant, rather than merely sociologically interesting, is the way in which the exclusion was naturalized. The RCT was not presented as one method among several, each with its domain of appropriate application. It was presented as the method—the procedure by which therapeutic claims could be adjudicated on their merits, free from the distortions of tradition, authority, or anecdote. This framing allowed the exclusion of Indigenous medicine to appear not as a philosophical choice but as a consequence of those traditions' failure to meet universal standards.
That framing is philosophically untenable. The standards in question are not universal. They are the product of a particular intellectual tradition—one with genuine strengths and genuine blind spots—and their application as universal arbiters has less to do with their demonstrated comprehensiveness than with the institutional power of those who adopted them.
This does not require the conclusion that all therapeutic claims are equally valid, or that evidence is merely a social construction. It requires the more modest and more defensible conclusion that the instruments by which evidence is gathered and evaluated are themselves theory-laden, historically situated, and subject to philosophical critique. American medicine's evidence hierarchy is not a view from nowhere. It is a view from somewhere specific, and the traditions it cannot see are not therefore invisible—only rendered so by the limits of its chosen optics.
Toward a More Capacious Epistemology
Some researchers within the fields of medical anthropology, integrative medicine, and Indigenous health studies have begun developing methodological alternatives—pragmatic trials, whole-systems research designs, and community-based participatory frameworks that attempt to evaluate therapeutic practices on terms more consonant with their own internal logics. These efforts are valuable, but they remain marginal within the institutional landscape of American biomedicine.
The deeper work is philosophical. It requires asking not merely how to measure Indigenous medicine, but why the current measuring apparatus was built as it was, whose interests it served, and what a genuinely pluralistic epistemology of therapeutic knowledge might look like. Those are questions that belong as much to the history and philosophy of science as to clinical research methodology. They deserve sustained attention from scholars in both traditions.
